英文摘要 |
Objective:Neuropsychiatric events result in increased steroid doses, comorbidity, and decreased the quality of life in patients with systemic lupus erythematosus (SLE). It remains to be identified how serum autoantibodies contribute to the development and severity of neuropsychiatric SLE (NPSLE). Methods:We retrospectively analyzed data from patients with SLE at a single medical center between January 2011 and December 2017. Clinical manifestations, including seizure, stroke, psychosis, mood disorders, myelopathy, and insomnia, were accounted for the analysis. Results:There was an adjusted odds ratio (OR) of 4.85 with a 95% confidence interval of 1.13 to 20.88 of a positive lupus anticoagulant test leading to the development of NPSLE, with a p value of 0.034. The area under the receiver operating characteristic (ROC) curve was 0.601 for the contribution of a positive lupus anticoagulant test for the development of NPSLE. The presence of serum anti-Ribosomal P antibody revealed an adjusted OR of 9.70*108, though no statistically significant effect was observed on the development of myelopathy. Conclusions:The presence of antiphospholipid antibodies and anti-Ribosomal P antibody in SLE, regardless of the levels, shows predictive value for neuropsychiatric events. Direct statistical association was not achieved in this analysis; elucidation of the direct predictive value of autoantibodies for NPSLE events requires a larger study population. |